ArticlePLoS pathogens2011
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation.
Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 97 citations in OpenAlex.
- Machine learning-driven discovery of host genetic factors for paratuberculosis in goats within the one health framework.BMC veterinary research · 2026Article
- Experimental Evidence That Prenatal and Postnatal Developmental Stress Affects the Adult Seminal Fluid Proteome in a Precocial Bird.Molecular ecology · 2026Article
- Synergistic effects of electrical and chemical cues with biodegradable scaffolds for large peripheral nerve defect regeneration.Bioactive materials · 2025Article
- A Prospective Study on Neural Biomarkers in Patients with Long-COVID Symptoms.Journal of personalized medicine · 2024Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- Review
- Emerging role of S100B protein implication in Parkinson's disease pathogenesis.Cellular and molecular life sciences : CMLS · 2021Review
- The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases.Pulmonary medicine · 2021Review
- Serum S100B protein as a marker of severity in Covid-19 patients.Scientific reports · 2020Article
- COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment.Journal of fungi (Basel, Switzerland) · 2020Review
- The Generation and Identity of Human Myeloid-Derived Suppressor Cells.Frontiers in oncology · 2020Review
- Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi.Frontiers in cellular and infection microbiology · 2020Review
- S100 proteins in obesity: liaisons dangereuses.Cellular and molecular life sciences : CMLS · 2020Review
- Cellular and molecular mechanisms of sarcopenia: the S100B perspective.Journal of cachexia, sarcopenia and muscle · 2018Review
- RAGE in the pathophysiology of skeletal muscle.Journal of cachexia, sarcopenia and muscle · 2018Review
- Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.World journal of pediatrics : WJP · 2018Review
- Effects of dexamethasone on the Li-pilocarpine model of epilepsy: protection against hippocampal inflammation and astrogliosis.Journal of neuroinflammation · 2018Article
- Oxidative stress-induced S100B accumulation converts myoblasts into brown adipocytes via an NF-κB/YY1/miR-133 axis and NF-κB/YY1/BMP-7 axis.Cell death and differentiation · 2017Article
- HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins.Cellular & molecular immunology · 2017Review
- Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model.Behavioral and brain functions : BBF · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humans inhale hundreds of Aspergillus conidia without adverse consequences. Powerful protective mechanisms may ensure prompt control of the pathogen and inflammation. Here we reveal a previously unknown mechanism by which the danger molecule S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. Upon forming complexes with TLR2 ligands, S100B inhibited TLR2 via RAGE, through a paracrine epithelial cells/neutrophil circuit that restrained pathogen-induced inflammation. However, upon binding to nucleic acids, S100B activated intracellular TLRs eventually resolve danger-induced inflammation via transcriptional inhibition of S100B. Thus, the spatiotemporal regulation of TLRs and RAGE by S100B provides evidence for an evolving braking circuit in infection whereby an endogenous danger protects against pathogen-induced inflammation and a pathogen-sensing mechanism resolves danger-induced inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.